Latest News
Via The Motley Fool · May 16, 2025
Via The Motley Fool · May 16, 2025
Precision measurement company Mettler-Toledo (NYSE:MTD) reported Q1 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 4.6% year on year to $883.7 million. Its non-GAAP profit of $8.19 per share was 3.9% above analysts’ consensus estimates.
Via StockStory · May 16, 2025
Industrial manufacturing company Ingersoll Rand (NYSE:IR) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.8% year on year to $1.72 billion. Its non-GAAP profit of $0.72 per share was 2.6% below analysts’ consensus estimates.
Via StockStory · May 16, 2025
Healthcare services company Select Medical (NYSE:SEM) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 2.4% year on year to $1.35 billion. The company’s full-year revenue guidance of $5.4 billion at the midpoint came in 1.6% below analysts’ estimates. Its GAAP profit of $0.44 per share was 7.3% below analysts’ consensus estimates.
Via StockStory · May 16, 2025
Infrastructure construction company MasTec (NYSE:MTZ) beat Wall Street’s revenue expectations in Q1 CY2025, with sales up 6% year on year to $2.85 billion. The company expects next quarter’s revenue to be around $3.4 billion, close to analysts’ estimates. Its non-GAAP profit of $0.51 per share was 50% above analysts’ consensus estimates.
Via StockStory · May 16, 2025
Internet, cable TV, and phone provider Cable One (NYSE:CABO) fell short of the market’s revenue expectations in Q1 CY2025, with sales falling 5.9% year on year to $380.6 million. Its non-GAAP profit of $12.58 per share was 3.1% above analysts’ consensus estimates.
Via StockStory · May 16, 2025
Gold remains under pressure despite a strong recovery from recent lows.
Via Talk Markets · May 16, 2025
Via The Motley Fool · May 16, 2025
Via The Motley Fool · May 16, 2025
US bank regulators are preparing to reduce bank capital requirements.
Via Talk Markets · May 16, 2025
The company intends to commence the phase 2 study of its lead program, TPI 287, to treat Glioblastoma Multiforme (GBM) by year-end.
Via Stocktwits · May 16, 2025
Inozyme Pharma is working on an enzyme replacement therapy for ENPP1 deficiency in children.
Via Investor's Business Daily · May 16, 2025
The European Commission argued that the fine is “modest” and only amounts to 0.5% of Intel’s current revenue.
Via Stocktwits · May 16, 2025
Via The Motley Fool · May 16, 2025
The bond market remains under pressure.
Via Talk Markets · May 16, 2025
NEAR Protocol debuts 600ms block time with 1.2s finality, enabling near-instant dApp experiences and real-time AI integration.
Via Stocktwits · May 16, 2025
AUD/USD stays above the key support level of 0.6400, while the US Dollar trades with caution.
Via Talk Markets · May 16, 2025
It's currently all systems go for this "Magnificent Seven" stock after the recent China-U.S. trade deal announcement.
Via The Motley Fool · May 16, 2025